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Abstract: Childhood overweight and obesity have reached epidemic proportions worldwide, and the increase in weight-
associated co-morbidities including premature type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease 
will soon become major healthcare and economic problems. A number of studies now indicate that the childhood obesity 
epidemic which has emerged during the past 30 years is a complex multi-factorial disease resulting from interaction of 
susceptibility genes with an obesogenic environment. This review will focus on gene-diet interactions suspected of having 
a prominent role in promoting childhood obesity. In particular, the specific genes that will be presented (FTO, MC4R, and 
NPC1) have recently been associated with childhood obesity through a genome-wide association study (GWAS) and were 
shown to interact with nutritional components to increase weight gain. Although a fourth gene (APOA2) has not yet been 
associated with childhood obesity, this review will also present information on what now represents the best characterized 
gene-diet interaction in promoting weight gain.  
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CHILDHOOD OVERWEIGHT AND OBESITY 
  The Centers for Disease Control and Prevention (CDC) 
defines childhood overweight as a body mass index (BMI) 
equal to and greater than the age and gender specific 85th 
percentile (BMI  85th percentile), where BMI is calculated 
as weight in kilograms divided by height in meters squared 
(BMI = kg/m
2) [1].
 This definition of childhood overweight 
includes the category of childhood obesity defined as a BMI 
equal to and greater than the age and gender specific 95th 
percentile (BMI  95th percentile). The most recent National 
Health and Nutrition Examination Survey (NHANES) 
indicates that childhood (2-11 years of age) overweight and 
obesity in the United States has approximately doubled 
during the past three decades, while adolescent (12-19 years 
of age) overweight and obesity has more than tripled during 
the same period [2]. This study also indicates that 9.5% of 
infants/toddlers (birth-2 years of age) and 16.9% of 
children/adolescents were at or above the 95th percentile of 
BMI, therefore categorized as being obese. On a global 
scale, a recent World Health Organization (WHO) nutritional 
survey obtained from 43 million children living in 144 
different countries indicates that preschool childhood 
overweight and obesity increased from 4.2% in 1990 to 6.7% 
in 2010, with prevalence expected to reach approximately 
9.1% by 2020 [3]. Childhood and adolescent overweight and 
obesity (referred to hereafter as childhood obesity) has 
reached epidemic proportions both nationally and 
internationally; consequently, increased weight-associated 
co-morbidities, including premature type 2 diabetes mellitus  
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(T2DM) and atherosclerotic cardiovascular disease, will 
soon represent major healthcare and economic problems [4].  
  For decades the primary causes of childhood obesity 
remained unknown, due in part to uncertainty about whether 
weight gain was caused by psychological or biological 
(genetic) factors [5]. For instance, in the early to middle 
parts of the twentieth century, studies suggested that 
psychological factors were primarily responsible for specific 
behavior (overconsumption of food) contributing to 
childhood obesity [6]. However, other studies performed 
using twins fed different diets and/or raised independently, 
in addition to the eventual cloning of a specific gene (leptin 
gene) associated with early-onset weight gain, suggested that 
genetic factors were also responsible for childhood obesity 
[7, 8]. But since the childhood obesity epidemic is a new 
phenomenon that has emerged only during the past 30 years, 
it is unlikely that genetic variation alone has significantly 
contributed to this healthcare problem. It is important to 
realize that the timing of this epidemic parallels increased 
availability of calorie-dense foods and a more sedentary 
lifestyle, in what is now commonly referred to as an 
“obesogenic environment”. Therefore, although genetic 
changes are not responsible for the increase in childhood 
obesity, the condition is probably the result of genetic 
susceptibility manifested in an obesogenic environment, 
most likely through complex and undefined gene-diet and 
gene-physical activity interactions.  
THRIFTY GENES AND INTERACTION WITH AN 
OBESOGENIC ENVIRONMENT 
  A presentation of gene-environment interactions should 
involve the concept of “thrifty genes”, which was first 
introduced by the American geneticist James V. Neel in 
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certain groups of people [9]. However, since publication of 
his original article, the vast majority of citations have been in 
reference to obesity. In brief, it was hypothesized that certain 
indigenous people with hunter-gatherer lifestyles 
experienced repeated periods of feast and famine, which 
through adaptation resulted in the natural selection of thrifty 
genes. These thrifty genes permitted efficient conversion of 
food calories into fat when food supplies were plentiful 
(feast portion of the cycle) and that fat was later used as an 
energy source when food was limited (famine portion of the 
cycle). However, the selective advantage of these thrifty 
genes soon became a disadvantage when these people were 
exposed to a chronic obesogenic environment characterized 
by a high-fat diet and sedentary lifestyle; in essence the 
continual and excessive storage of fat prepared these people 
for a famine that never arrived. As a result, the existence of 
thrifty genes among certain groups of people, the most 
studied and documented of which include the Pima Indians 
of Arizona, may be responsible for excessive weight gain 
and associated T2DM [10, 11]. Although the concept of 
thrifty genes remains valid, there has recently been much 
debate concerning potential fundamental flaws involving the 
original hypothesis [12, 13]. The controversial points include 
whether hunter-gatherers actually experienced severe enough 
famines for natural section of thrifty genes, and if severe 
enough famines happened to exist whether natural selection 
could have been mediated through other means such as 
fertility, instead of viability [13, 14]. As a result of these 
debates, additional and more comprehensive hypotheses 
have emerged. These hypotheses include a network of five 
non-mutually exclusive genotypes (thrifty, hyperphagic, 
sedentary, low lipid oxidation, and adipogenesis), in addition 
to the possible involvement of genome plasticity proposing 
that genes may interact with components in the current 
obesogenic environment to increase weight gain and obesity 
[15, 16]. 
  Finally, since the human population is genetically diverse 
and heterogenous with over 7.7 million single nucleotide 
polymorphisms (SNPs), identifying and investigating 
potential gene-diet interactions in relation to various human 
diseases including obesity is further complicated by gene-
gene interactions. The many different and simultaneous 
gene-gene interactions therefore contribute to what is 
commonly referred to as a multi-factorial or polygenic 
disease. As a result, to circumvent this inherent difficulty in 
identifying and investigating gene-diet interactions related to 
weight gain and obesity, researchers have necessarily used 
genetically identical mouse models that possess only one 
specific gene variant of interest.  
GENE-DIET INTERACTIONS CONTRIBUTING TO 
CHILDHOOD OBESITY 
  Although a number of genes are associated with either 
weight gain or obesity, few have definitively been shown to 
interact with diet and contribute to early-onset or childhood 
obesity [17]. One particular GWAS recently identified the 
first genes associated with early-onset (before 6 years of age) 
and extreme childhood and morbid adult obesity (BMI  40 
kg/m
2) [18]. In brief, the study used nearly 1,400 obese 
Europeans compared to a similar number of age-matched 
normal weight controls for the first step or discovery stage, 
in addition to 2,100 obese and 2,400 normal weight 
individuals for the second step or confirmatory stage, and 
then 9,700 individuals from the general population for the 
third step or re-confirmatory stage. The five genes found to 
be associated with childhood obesity included the fat mass 
and obesity associated (FTO) gene, the melanocortin-4 
receptor (MC4R) gene, the Niemann-Pick C1 (NPC1) gene, 
the musculoaponeurotic fibrosarcoma (MAF) gene, and the 
phosphotriesterase-related (PTER) gene. Recent studies 
indicate that three of these genes (FTO, MC4R, and NPC1) 
interact with a high-fat diet to promote early-onset or 
childhood obesity. Therefore, a more comprehensive review 
of these specific genes will be presented in this article. 
Moreover, although the apolipoprotein A-2 (APOA2) gene 
has not been found to be associated with childhood obesity 
in a GWAS, this review will also present information on 
what now represents the best characterized gene-diet 
interaction in promoting increased weight gain. It is 
important to emphasize that due to the complexity of 
elucidating gene-diet interactions in a heterogeneous human 
population, studies performed using mouse models will be 
emphasized.  
THE FAT MASS AND OBESITY ASSOCIATED GENE 
  The fat mass and obesity associated (FTO) gene 
represents the first gene identified that contributes to 
common forms of human obesity [19]. The FTO gene, 
located on the long arm of human chromosome 16 within 
cytogenetic band q12.2, encodes a protein classified within 
the non-heme dioxygenase (Fe(II) and 2-oxoglutarate-
dependent dioxygenase) superfamily of proteins due to 
extensive conservation of amino acid sequence [20, 21]. The 
encoded FTO protein is localized to the nucleus where it 
catalyzes demethylation of certain nucleic acid bases (1-
methyladenine, 3-methylthymine, and 3-methylcytosine) 
associated with single-stranded RNA or DNA (Fig. 1). The 
FTO gene is ubiquitously expressed in both mouse and 
human tissues, with the highest amounts of messenger RNA 
found in the arcuate hypothalamus and regulated by 
fasting/feeding cycles. This provided the first evidence that 
the FTO protein possessed an important regulatory role in 
maintaining energy balance [20, 22]. Although the molecular 
basis for how the FTO protein maintains energy balance 
remains undefined, two recent studies suggest that FTO gene 
variants are associated with promoting increased weight 
gain. In the first of these studies, overweight individuals 
(BMI   25 kg/m
2) who were either heterozygous or 
homozygous for a common FTO gene variant (rs9939609) 
had significantly decreased cerecortical beta-activity 
compared to lean individuals (BMI  25 kg/m
2) without the 
FTO gene variant [23]. This result suggested that individuals 
with the FTO gene variant had brain insulin resistance, 
consistent with a previous study demonstrating that proper 
insulin-induced brain signaling was necessary for satiety and 
appetite control in maintaining energy balance [24]. In the 
second study, subcutaneous adipose tissue biopsies obtained 
from a cohort of 306 healthy women (BMI = 18-53 kg/m
2) 
indicated that individuals heterozygous for the common FTO 
gene variant had increased in vitro adipocyte glycerol release 
(22%) and in vivo plasma glycerol levels (30%), suggesting 
that the FTO protein had an undefined role in regulating the 
hydrolysis of triacyglycerol within adipocytes [25]. 182    Current Genomics, 2011, Vol. 12, No. 3  William S. Garver 
 The  corresponding Fto gene in mice was first identified 
as a result of generating a transgenic mouse model that 
coincidently caused deletion of a genomic region containing 
the Fto gene [26]. Several years later, a GWAS designed to 
identify genes associated with T2DM in both adults and 
children detected the FTO gene, which after adjustment for 
BMI revealed that the FTO gene was actually associated 
with BMI and not T2DM [19]. Another GWAS published 
the same year with 442 lean and 487 extremely obese 
German children/adolescents indicated that the FTO gene 
had a strong association with extreme early-onset or 
childhood obesity [27]. Moreover, another study performed 
using 234 full-term healthy newborns (112 boys and 122 
girls) also indicated an association between FTO gene 
variants, abdominal fat mass, and body weight at only two 
weeks of age [28]. The most recent GWAS has confirmed 
that the FTO gene, in addition to two other obesity 
susceptibility genes (MC4R and NPC1, reviewed below) are 
associated with childhood and adult obesity within a 
European population [18]. However, not all individuals 
possessing  FTO gene variants are overweight or obese, 
suggesting that possible interactions with other genetic 
and/or environmental factors could be necessary for 
promoting weight gain and obesity [29]. 
  Recent studies provide valuable insight into the 
molecular basis for how FTO gene variations promote 
weight gain. In brief, FTO gene variants in both children and 
adults are associated with increased energy consumption and 
decreased satiety [30, 31]. Consistent with these results, 
studies performed using Fto deficient mice (Fto
-/-) indicated 
a relative increase in energy consumption [32]. These results 
provided the first evidence indicating that FTO gene variants 
may interact with environmental factors, such as the diet, to 
promote weight gain. With respect to a potential FTO gene-
diet interaction in promoting increased BMI, a cross-
sectional study of 4,839 adults demonstrated a significant 
interaction between the common FTO gene variant and 
dietary fat in relation to increased BMI after adjustment for 
total energy consumption [33]. Moreover, another study 
performed using 289 children and adolescents between 6-19 
years of age with the common FTO gene variant indicated 
that although total energy consumption did not differ 
significantly from controls, individuals with the FTO gene 
variant consumed a greater percentage of calories derived 
from fat [34]. These results indicate that individuals who 
possess FTO gene variants have an increased preference for 
calorie-dense foods enriched with fat and decreased satiety, 
factors responsible for promoting weigh gain and childhood 
obesity. 
THE MELANOCORTIN 4-RECEPTOR GENE 
  The melanocortin 4-receptor (MC4R) gene is responsible 
for the most common forms of childhood and adult obesity. 
The  MC4R gene, located on the long arm of human 
chromosome 18 within cytogenetic band q21.32, encodes a 
large and complex plasma membrane protein belonging to 
the family of seven transmembrane G protein-coupled 
receptors that activate the adenylate cyclase-dependent 
pathway responsible for cAMP signaling [35, 36]. The 
MC4R gene is primarily expressed in the paraventricular 
nucleus of the hypothalamus, where an endogenous agonist 
(alpha-melanocyte stimulating hormone or -MSH) and 
antagonist (agouti-related protein or AgRP) compete for 
binding to the MC4R protein [37]. Activation of the MC4R 
protein by binding -MSH results in decreased feeding and 
increased energy expenditure through thermogenesis, while 
deactivation of the MC4R protein by binding AgRP inhibits 
this process and therefore decreases satiety and energy 
expenditure [38]. Secretion of insulin and leptin, both found 
to be directly associated with the amount of adipose tissue, 
has an indirect role in maintaining energy balance through 
the MC4R pathway by stimulating synthesis of 
proopiomelanocortin (POMC) from POMC neurons, which 
is then processed to -MSH capable of being bound by the 
MC4R protein (Fig. 2) [39]. As might be expected, genetic 
variation resulting in loss of function for the MC4R, LEP, 
and POMC genes contributes to weight gain and obesity. 
  The first definitive study demonstrating that the MC4R 
gene has a role in promoting obesity was performed by 
targeted disruption of this gene (Mc4r) within mice; this 
explained excessive weight gain in what was commonly 
referred to as the agouti mouse model [40, 41]. In this study, 
the  Mc4r heterozygous (Mc4r
+/-) mice were characterized 
with intermediate weight gain when compared to Mc4r 
normal (Mc4r
+/+) and Mc4r homozygous (Mc4r
-/-) mice, 
indicating codominant inheritance. Soon after, two different 
frameshift mutations were identified in a severely obese 
child (10 years of age, BMI = 34 kg/m
2) and a non-related 
obese middle aged woman (35 years of age, BMI = 30 
kg/m
2) known to have developed obesity during infancy [42, 
43]. Consistent with studies performed using Mc4r mice, the 
 
 
 
 
 
 
 
Fig. (1). The biochemical reaction catalyzed by 2-oxoglutarate oxygenase encoded by the FTO gene is responsible for demethylating certain 
nucleic acid bases (1-methyladenine, 3-methylthymine, and 3-methylcytosine) when associated with single-stranded RNA or DNA. Studies 
indicate that FTO gene variants interact with the diet by increasing preference for a specific nutrient (fat) and decreasing satiety to promote 
weight gain. 
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first large study performed using patients with MC4R 
mutations indicated a codominant mode of inheritance [44]. 
A number of later studies then identified three types of 
MC4R gene variants, which included more than a hundred 
loss-of-function mutations responsible for promoting 
obesity, two gain-of-function mutations protecting from 
obesity, and a frequent intergenic polymorphism associated 
with a modest increase in risk for obesity [42, 45]. Together, 
these  MC4R gene variants have not only been associated 
with promoting and protecting from obesity, but also with 
traits related to the intake and preference for foods. 
However, similar to the FTO gene, not all individuals 
possessing  MC4R gene variants are overweight or obese, 
again suggesting that possible interactions with other genetic 
and/or environmental factors could be necessary for 
promoting weight gain and obesity. 
  In comparison to Mc4r
+/+ mice fed a moderately high-fat 
diet, the Mc4r
-/-  mice were found to have hyperphagia, in 
addition to a partial defect in energy expenditure 
characterized by decreased diet-induced activity and 
thermogenesis [46, 47]. Consistent with these results, 
another study demonstrated that compared to Mc4r
+/+ mice, 
the Mc4r
-/- mice had hyperphagia when fed a high-fat diet, 
but not when fed a low-fat diet. This finding provided the 
first evidence for a gene-diet interaction in relation to weight 
gain in these mice [48]. An extension of these studies 
demonstrated that Mc4r
-/- mice fed a high-fat diet developed 
severe hepatic steatosis and insulin resistance, characterized 
in part by impaired fasting glucose and insulin tolerance, 
suggesting that these mice were also susceptible to features 
associated with T2DM [49]. Furthermore, recent studies 
have indicated that individuals possessing MC4R gene 
variants tend not only to consume increased amounts of 
food, but also prefer specific nutrients (total and saturated 
fat) [50]. A genome-wide linkage study performed to 
identify chromosomal regions contributing to increased 
dietary consumption and decreased physical activity among 
1,030 Hispanic children has provided strong evidence that 
MC4R gene variants have a role in regulating body weight 
through both energy consumption and expenditure [51, 52]. 
Although the molecular basis remains undefined and 
penetrance varies considerably among individuals, these 
results are consistent with individuals that possess MC4R 
gene variants having an increased preference for calorie-
dense foods enriched with fat and decreased satiety 
responsible for promoting weight gain and childhood 
obesity. 
THE NIEMANN-PICK C1 GENE 
  The Niemann-Pick C1 (NPC1) gene has been primarily 
investigated in relation to an autosomal-recessive lipid-
storage disorder characterized by neonatal jaundice, 
hepatosplenomegaly, and progressive neurodegeneration 
resulting in death during the second decade [53, 54]. The 
NPC1 gene, located on the long arm of human chromosome 
18 within cytogenetic band q11.2 near the centromere, 
encodes a large and complex multi-spanning transmembrane 
protein with extensive structural homology with members of 
the resistance-nodulation-division (RND) family of 
prokaryotic permeases [55, 56]. Considering the various 
structural motifs, the NPC1 protein contains 13 membrane-
spanning helices and 3 large luminal domains, among which 
an N-terminal domain (NTD) and sterol-sensing domain 
(SSD) independently bind cholesterol [57, 58]. The NPC1 
protein is associated with a unique late endosomal 
compartment that transiently interacts with low-density 
lipoprotein (LDL)-derived cholesterol enriched late 
endosomes/lysosomes; it facilitates the transport of 
cholesterol and possibly other lipids (fatty acids) to various 
cellular compartments, including the trans-Golgi network, 
plasma membrane, and endoplasmic reticulum [59, 60]. 
Although the exact function of the NPC1 protein remains 
undefined, studies have demonstrated that expression of the 
NPC1 gene is regulated through the sterol regulatory 
element-binding protein (SREBP) pathway, consistent with 
the NPC1 protein having a central role in maintaining 
cellular, tissue, and whole body lipid homeostasis (Fig. 3) 
[61, 62]. 
  In retrospect, a number of early studies performed using 
both  NPC1 human fibroblasts and the BALB/cJ NPC1 
 
 
 
 
 
 
 
 
 
 
Fig. (2). The insulin and leptin-melanocortin signaling pathway is responsible for maintaining energy and metabolic balance by controlling 
appetite. The melanocortin-4 receptor (MC4R) encoded by the MC4R gene binds to peptide hormones (-MSH or AgRP) secreted from 
either -MSH or AgRP expressing neurons, respectively, present in the arcuate nucleus of the hypothalamus. Studies indicate that MC4R 
gene variants interact with the diet by increasing preference for a specific nutrient (fat) and decreasing satiety to promote increased weight 
gain. AgRP, agouti-related peptide; POMC, proopiomelanocortin; -MSH, -melanocyte stimulating hormone. 
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mouse model revealed information concerning the potential 
involvement of the NPC1 protein in maintaining energy 
balance. For instance, NPC1 heterozygous (NPC1
+/-) human 
fibroblasts have increased expression of caveolin-1, which 
serves as a protein marker for obesity and T2DM [63, 64]. 
These results were confirmed and extended using Npc1 
heterozygous (Npc1
+/-) mice, which compared to Npc1 
normal (Npc1
+/+) and Npc1 homozyous (Npc1
-/-) mice, had 
livers with an increased expression of caveolin-1 and 
concentration of triacylglycerol, which is a prominent 
metabolic feature of obesity [65-67]. Together, these results 
were consistent with increased expression of caveolin-1 
having a central role in the transport of fatty acids (not 
cholesterol) and storage of triacylglycerol within lipid 
storage bodies involved in maintaining energy balance [68, 
69].  
  A recent GWAS revealed that the NPC1 gene was 
associated with early-onset and morbid adult obesity in 
European populations, but researchers did not know whether 
the  NPC1 gene non-synonymous SNPs (rs1805081 and 
rs1805082) increased or decreased corresponding NPC1 
protein function. At that time our group was performing a 
candidate-gene based mouse study using the NPC1 mouse 
model, which possesses a retroposon insertion resulting in a 
null mutation characterized by a severely truncated and non-
functional NPC1 protein [70, 71]. The results from this study 
demonstrated that when compared to Npc1
+/+ mice, the 
Npc1
+/- mice were characterized with significant weight gain 
when fed a high-fat diet, but not when fed a low-fat diet, 
consistent with a gene-diet interaction [72]. However, it must 
be emphasized, that similar to human NPC1 disease, the 
Npc1
-/- mice suffer from neurological degeneration, weight 
loss, and die before adulthood. To confirm the presence of an 
Npc1 gene-diet interaction in relation to weight gain in the 
Npc1
+/- mice, comprehensive statistical analyses of the 
growth data was performed using both fitted growth 
trajectories and estimated marginal means of body weight. 
The results demonstrated that only Npc1
+/- mice fed a high-
fat diet (not a low-fat diet) were susceptible to weight gain, 
thereby providing the first evidence of a gene-diet interaction 
in relation to weight gain [73]. 
  To further investigate the Npc1 gene-diet interaction in 
relation to weight gain and associated metabolic features, 
BALB/cJ  Npc1
+/- mice were interbred with wild-type 
C57BL/6J mice; the latter mouse strain commonly used to 
study aspects of diet-induced obesity and T2DM [74, 75]. 
This breeding produced a hybrid (BALB/cJ-C57BL/6J) 
NPC1  mouse model, for which the Npc1
+/- mice were 
characterized with weight gain, abdominal adiposity, 
adipocyte hypertrophy, hepatic steatosis, plasma 
dyslipidemia, and impaired glucose tolerance in the absence 
of hyperphagia [76]. Results from this second study were 
similar to the initial study using the BALB/cJ NPC1 mouse 
model, since an Npc1 gene-diet interaction was found to 
promote both weight gain and metabolic features associated 
with insulin resistance. Although further studies are required, 
these results are consistent with decreased Npc1 gene dosage 
or Npc1 haploinsufficiency in mice interacting with a high-
fat diet to either increase lipogenesis and/or storage of fat, or 
decrease energy expenditure (thermogensis and/or activity) 
to promote weight gain.  
THE APOLIPOPROTEIN A-2 GENE 
  The apolipoprotein A-2 (APOA2) gene is a member of 
the apolipoprotein multigene (APOA1, APOA2, and APOA4) 
family that shares a common genomic structure and 
possesses a range of diverse and complex physiological 
functions that remain undefined. The APOA2 gene, located 
on the long arm of human chromosome 1 within cytogenetic 
band q23.3, encodes a protein that is primarily associated 
with high density lipoprotein (HDL) in plasma [77]. 
Although a number of early studies suggested that the 
APOA2 protein had a functional role in regulating the 
transport of cholesterol from peripheral tissues back to the 
liver for excretion, subsequent studies were unable to 
confirm these results [78, 79]. To date, the physiological 
function for the APOA2 protein is instead believed to have a 
central role in regulating fatty acid and triacylglycerol 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). The NPC1 protein encoded by the NPC1 gene regulates the transport of lipids (cholesterol and fatty acids) from late 
endosomes/lysosomes to other cellular compartments to maintain intracellular, tissue, and whole body lipid homeostasis. Although human-
based studies have not yet been performed investigating the molecular basis for the NPC1 gene-diet interaction, studies performed using an 
NPC1 mouse model indicates that decreased Npc1 gene dosage or Npc1 haploinsufficiency resulting from a null mutation interacts with a 
high-fat diet to promote weight gain. 
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metabolism by modulating lipoprotein lipase-mediated 
hydrolysis of triacylglycerol [80, 81].  
  Since it was determined that the APOA2 protein had a 
role in regulating fatty acid and triacylglyerol metabolism, 
subsequent studies were performed investigating the APOA2 
protein in relation to adiposity and weight gain using both 
mouse models and humans. Studies using Apoa2 transgenic 
mice expressing increased amounts of APOA2 protein 
showed that in addition to promoting increased liver 
lipogenesis, the APOA2 protein inhibited hydrolysis of 
triacylglycerol stored within adipose tissues (epididymal and 
retroperitoneal), thereby accounting for weight gain in these 
mice [82]. A subsequent study demonstrated that metabolic 
dysregulation present in the Apoa2 transgenic mice resulted 
from reduced skeletal muscle fatty acid oxidation, skeletal 
muscle insulin resistance, and whole body compensatory 
hyperinsulinemia [83]. Researchers proposed that 
hyperinsulinemia increased both hepatic lipogenesis and 
secretion of VLDL resulting in hypertriacylglycerolemia and 
reduced hydrolysis of triacylglycerol in adipose tissues (Fig. 
4). Together, these results were consistent with an earlier 
study performed using Apoa2 knock-out (Apoa2
-/-) mice 
characterized with insulin hypersensitivity, decreased plasma 
triacyglycerol, and normal body weight [84]. Moreover, 
cross-breeding experiments using different mouse strains to 
identify genetic loci indicated that the Apoa2 gene was 
associated with increased mouse adiposity and body weight 
[85, 86]. With respect to initial studies performed using 
humans, an APOA2 SNP (rs5082) located within the APOA2 
promoter region resulting in decreased amounts of APOA2 
protein was associated with decreased waist circumference in 
men, but increased waist circumference in women, both in 
the absence of significant differences in either body weight 
or BMI [87, 88]. A later study investigating the same APOA2 
SNP reported that individuals who were APOA2 
heterozygous (APOA2
+/-) and APOA2 homozygous (APOA2
-/-) 
had a lower postprandial response (decreased postprandial 
hypertriacylglycerolemia) compared to individuals who were 
APOA2 normal (APOA2
+/+)  when consuming a high 
saturated-fat diet with no significant difference noted for 
body weights between the group of individuals [89]. 
Therefore, although Apoa2 mouse models had clearly 
demonstrated that increased expression of the APOA2 
protein was associated with increased adiposity and weight 
gain, the physiological role of APOA2 protein in humans 
remained controversial due to seemingly contradictory 
results.  
  More recent studies of the APOA2 gene clarified the role 
of the APOA2 protein in regulating adiposity and body 
weight by demonstrating that the APOA2 gene interacts with 
a high-fat diet to promote weight gain and obesity. The first 
of these studies, the Genetics of Lipid Lowering Drugs and 
Diet Network (GOLDN) study, used 1,078 individuals (514 
men and 564 women) [90]. The results indicated that 
APOA2
-/- individuals consumed increased amounts of food 
composed of fat and protein, in addition to having an 
increased body weight, BMI, and waist circumference 
compared to either APOA2
+/+  or  APOA2
+/-  individuals. 
Together these results suggested that the APOA2 protein 
served to regulate satiety and appetite control. A second 
study was then performed using 3,462 individuals obtained 
from 3 independent populations (Framingham Offspring 
Study with 1454 whites, GOLDN study with 1078 whites, 
and Boston-Puerto Rican Centers on Population Health and 
Health Disparities study with 903 Hispanics). The study was 
specifically designed to search for interactions occurring 
between the APOA2 SNP (rs5082) and consumption ( 22 g 
per day) of saturated fat [91]. The results indicated a 
significant interaction between APOA2
-/- individuals and 
consumption of saturated fat in relation to an increase in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). The APOA2 protein encoded by the APOA2 gene has an undefined role in regulating fatty acid and triacylglyerol metabolism in at 
least two tissues (skeletal muscle and adipose) to maintain energy balance. Although the molecular basis remains undefined, studies indicate 
that the APOA2 gene variants interact with saturated fats to promote weight gain in diverse populations of adult individuals. 
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BMI for all 3 populations. These individuals had a 6.2% 
greater increase in BMI when consuming a high-saturated fat 
diet, but not when consuming a low-saturated fat diet, 
compared to either APOA2
+/+ or APOA2
+/-  individuals. A 
third study recently used 4,602 individuals obtained from 2 
additional populations (a high-cardiovascular risk 
Mediterranean population with 907 men and women, and a 
multiethnic Asian population with 2,506 Chinese, 605 
Malays, and 494 Asian Indians). This study was specifically 
designed to investigate possible interactions between the 
APOA2 SNP (rs5082) and consumption ( 22 g per day) of 
saturated fat [92]. Consistent with the previous two studies, 
the results indicated a significant interaction between 
APOA2
-/- individuals and consumption of saturated fats in 
relation to an increase in BMI in the 2 populations; these 
individuals had a 6.8% greater increase in BMI when 
consuming a high-saturated fat diet, but not when consuming 
a low-saturated fat diet, compared to either APOA2
+/+  or 
APOA2
+/- individuals. Therefore, these results obtained from 
three independent and diverse populations with large sample 
sizes provide the first consistent evidence of a gene-diet 
(APOA2 gene and saturated fat) interaction in promoting 
increased weight gain and human obesity, although the 
molecular basis for the weight gain remains undefined.  
CONCLUSION 
  Researchers now appreciate that common obesity 
represents a complex multi-factorial disease resulting from 
the interaction of susceptibility genes with an obesogenic 
environment characterized by increased consumption of 
energy-dense foods or specific nutrients and a sedentary 
lifestyle. Given the current epidemic of childhood obesity, 
continued investigation of gene-diet interactions will be 
important for several reasons. First, most diseases, if not all 
diseases, and associated outcomes result from an undefined 
and complex interaction between susceptibility or modifying 
genes and various environmental factors [17, 93, 94]. With 
respect to the susceptibility genes outlined in this review, 
each gene interacts with specific macronutrients (high-fat 
food or high saturated-fat food) to promote obesity [95]. 
Second, the search and identification of gene-diet 
interactions should be at the forefront in attempts to 
understand both the etiology and pathophysiology of 
nutrition-related diseases, particularly childhood obesity 
[96]. And third, the interaction of specific genetic variations 
with a known dietary component could eventually lead to 
more detailed population-based studies to identify and 
provide targeted treatment for individuals at increased risk of 
developing childhood obesity [97, 98]. The goal for 
investigating gene-diet interactions would be to abandon the 
erroneous notion that for potential nutrition-based 
interventions “one size fits all.” Instead, a plausible 
mechanism-based approach to personalized nutritional 
and/or medicinal therapy will more effectively address the 
current epidemic of childhood obesity.  
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